A Study of SIPLIZUMAB in AILD and LT Patients
A Study of SIPLIZUMAB in AILD and LT Patients
Recruiting · NCT06455280 · Registry updated 2025-11-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of SIPLIZUMAB in AILD and LT Patients | Cholangitis, Sclerosing, Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Hepatitis, Chronic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune hepatitis, bile duct disorder, biliary tract disorder, cholangitis, chronic liver failure, cirrhosis of liver, hepatitis, immune system disorder, liver disorder, liver failure, primary sclerosing cholangitis | Recruiting | Phase 1 | 2025-11-24 | NCT06455280 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Elizabeth C. Verna | 1 |
| ITB-Med LLC | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Columbia University Irving Medical Center/NewYork-Presbyterian Hospital | New York | United States | 4 |